Keros Therapeutics (KROS): CEO received 63K units

63K

Derivative units

Traded

Jan 7, 2026

Filed

Jan 9, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

What came next

1. Feb 18, 2026Insider · 3 peopleInsiders: 3 sales (~$218K)
2. Feb 19, 2026InsiderCEO sold ~$113K of KROS shares in the open market
3. Feb 20, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 24, 2026, the board of directors (the “Board”) of Keros Therapeutics, Inc. (the “Company”), based upon a recommendation from the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), voted to appoint Charles Newton as a director of the Company, effective on March 9, 2026.”
4. Mar 4, 2026Company filing · Form 8-K · ResultsReported its results
5. Mar 9, 2026Insider · Their first buy on recordDirector purchased ~$22K of KROS shares in the open market
6. Apr 15, 2026InsiderDirector purchased ~$12K of KROS shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Keros Therapeutics

For Keros Therapeutics, OQRO holds 6 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KROS page.

Other recent filings by Jasbir Seehra, CHIEF EXECUTIVE OFFICER

• SEC Form 4 at Keros Therapeutics (KROS)Feb 20, 2026

The full history of Jasbir Seehra, CHIEF EXECUTIVE OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Keros Therapeutics

• SEC Form 144Nov 12, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 19, 2026

Everything OQRO holds on this company is on its KROS page.